ACI Worldwide, Inc. (ACIW)
NASDAQ: ACIW · Real-Time Price · USD
40.74
-1.82 (-4.28%)
At close: Aug 1, 2025, 4:00 PM
41.48
+0.74 (1.82%)
After-hours: Aug 1, 2025, 5:40 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CTI BioPharma stock have an average target of 60, which predicts a 47.28% increase from the current stock price of 40.74.
Price Target: $60.00 (+47.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 3 | 3 | 3 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Hold → Buy Upgrades $60 | Hold → Buy | Upgrades | $60 | +47.28% | Jul 17, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $68 → $60 | Strong Buy | Maintains | $68 → $60 | +47.28% | May 27, 2025 |
| DA Davidson | DA Davidson | Hold → Strong Buy Upgrades $60 | Hold → Strong Buy | Upgrades | $60 | +47.28% | May 12, 2025 |
| DA Davidson | DA Davidson | Strong Buy → Hold Downgrades $57 → $60 | Strong Buy → Hold | Downgrades | $57 → $60 | +47.28% | Nov 8, 2024 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 18, 2024 |
Financial Forecast
Revenue This Year
1.74B
from 1.59B
Increased by 9.14%
Revenue Next Year
1.86B
from 1.74B
Increased by 6.78%
EPS This Year
2.39
from 1.91
Increased by 24.96%
EPS Next Year
2.54
from 2.39
Increased by 6.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.8B | 2.0B | 2.0B |
| Avg | 1.7B | 1.9B | 1.9B |
| Low | 1.7B | 1.7B | 1.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.7% | 12.4% | 6.9% |
| Avg | 9.1% | 6.8% | 3.9% |
| Low | 4.2% | 0.5% | -0.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.64 | 2.84 | 2.72 |
| Avg | 2.39 | 2.54 | 2.64 |
| Low | 2.20 | 2.24 | 2.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 38.0% | 18.8% | 7.1% |
| Avg | 25.0% | 6.4% | 4.0% |
| Low | 14.9% | -6.0% | -0.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.